

# PURC

PURC, a quality improvement initiative, brings urology practices together in a physician-led data-sharing collaborative aimed at advancing the quality of prostate cancer diagnosis and care.

2017 AUA Risk Stratification for Localized Prostate Cancer	
<b>Very Low Risk</b>	PSA < 10 ng/ml AND Grade Group 1 AND clinical stage T1 - T2a AND <34% of biopsy cores positive AND no core with >50% involved, AND PSA density < 0.15 ng/ml/cc
<b>Low Risk</b>	PSA < 10 ng/ml AND Grade Group 1 AND clinical stage T1 - T2
<b>Favorable Intermediate Risk</b>	Grade Group 1 (with PSA 10 - <20) OR Grade Group 2 (with PSA < 10)
<b>Unfavorable Intermediate Risk</b>	Grade Group 2 (with either PSA 10 - <20 or clinical stage T2b - c) OR Grade Group 3 (with PSA < 20)
<b>High</b>	PSA > 20 ng/ml OR Grade Group 4 - 5 OR clinical stage ≥ T3*

\*Clinical stage T3 cancer is considered locally advanced.

## Imaging Recommendations by Risk Category

2017 AUA Recommendations\*

Risk Category	Axial Imaging	Bone Scan
<b>Very Low</b>	+/- MRI	None
<b>Low</b>	+/- MRI	None
<b>Favorable Intermediate</b>	+/- MRI	None
<b>Unfavorable Intermediate</b>	CT or MRI	Yes
<b>High</b>	CT or MRI	Yes



For more information, please contact Claudette Fonshell at [cfonshell@hcfonline.org](mailto:cfonshell@hcfonline.org) or 215-575-3747.

\*Source: [http://www.aunet.org/guidelines/clinically-localized-prostate-cancer-new-\(aua/astro/suo-guideline-2017\)](http://www.aunet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017))